BioThink, Vol -2, Issue -2
ISSN: 3048-7943

Bronchitis and COPD: Advances in Diagnosis, Treatment, and Prevention

Hem Lata[1], Akshita Kumari[1], Ritika Chauhan[1], Nikhil Prashar[1], Isha Thakur[1], Subham Kapil[1,2*], Pankaj Bagga[3]

[1]Department of Biosciences, Career Point University, Bhoranj (Tikker-Kharwarian) Hamirpur, Himachal Pradesh (India) – 176041, [2]Centre for Green Energy Research, Career Point University, Bhoranj (Tikker-Kharwarian) Hamirpur, Himachal Pradesh (India) – 176041, [3]Department of Zoology, DAV College, Jalandhar Punjab (India)-144008.

Corresponding author: *Subham Kapil (shubhamkapil143@gmail.com)*

Introduction

Bronchitis is a respiratory disorder affecting the bronchi, resulting in coughing and mucus production. There are two types of bronchitis: acute and chronic. Acute bronchitis is a temporary disease, whereas chronic bronchitis is long-term. Acute bronchitis is primarily caused by viruses or bacteria and occurs when inflammation develops in the bronchi of the lungs (Smith et al., 2020). It affects approximately 5% of adults annually and is more prevalent in winter and fall compared to summer and spring. The incidence of acute bronchitis is about 29 episodes per thousand person-years, accounting for over 20% of respiratory tract illnesses (Buhagiar, 2009). Acute bronchitis is a self-limiting condition, and antibiotics are generally not required unless pneumonia is suspected.

The primary cause of acute bronchitis is viral infection, with common pathogens including rhinovirus, influenza A and B, parainfluenza, coronavirus, human metapneumovirus, and respiratory syncytial virus. A small percentage (1-10%) of cases involve bacterial infections caused by Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae (Kinkade et al., 2016; Macfarlane et al., 2001). The main symptom of acute bronchitis is coughing, and distinguishing it from conditions such as asthma, chronic obstructive pulmonary disease (COPD), heart failure, or pneumonia is a key diagnostic priority (Wenzel et al., 2006). Other symptoms include sputum production, headache, fever, nasal congestion, and dyspnea.

Chronic Bronchitis

Chronic bronchitis is a subtype of chronic obstructive pulmonary disease (COPD) that affects individuals of various age groups, though it is more commonly diagnosed in

those aged 45 and older. It results from prolonged exposure to lung irritants such as cigarette smoke, air pollution, chemical fumes, and environmental dust, which lead to persistent inflammation and mucus overproduction in the airways (Mukherjee et al., 2009; Longe et al., 2006). Among these irritants, cigarette smoking is the leading cause, contributing significantly to disease progression and complications.

Types of Chronic Bronchitis

Chronic bronchitis can be classified into two main types based on airflow obstruction and disease severity:

1. **Simple Chronic Bronchitis:** This form does not involve significant airflow obstruction in pulmonary function tests. However, some patients may develop chronic obstructive bronchitis, which is characterized by reduced airflow rates, particularly during exhalation, leading to breathing difficulties (Mukherjee et al., 2009; Breslow et al., 2002). The hallmark symptom is a persistent cough with mucus production (yellow, white, or green sputum) for at least three months per year over two consecutive years (Mukherjee et al., 2009; Feeney et al., 2004). While smoking is the primary cause in adults, in children, a similar condition known as protracted bacterial bronchitis (PBB) can occur due to recurrent bacterial infections (Widysanto, 2025).
2. **Chronic Obstructive Bronchitis:** This is a more severe form of COPD characterized by progressive lung function decline. Patients with this condition, particularly smokers, are at a higher risk of recurrent respiratory infections, frequent exacerbations, and increased mortality. The disease is driven by excessive mucus production due to the overactivation of goblet cells and chronic airway inflammation, leading to persistent airflow limitation (Kim & Criner, 2013).

Epidemiology and Causes

Bronchitis, in general, is a common respiratory condition, with acute bronchitis affecting approximately 5% of adults annually, particularly during the winter and fall seasons. It accounts for around 23% of respiratory tract infections in adults (Buhagiar, 2009). The most frequent cause of acute bronchitis is viral infections,

including rhinovirus, influenza A and B, parainfluenza, coronavirus, human metapneumovirus, and respiratory syncytial virus. Bacterial causes are less common but can include Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae (Kinkade et al., 2016).

In contrast, chronic bronchitis is predominantly diagnosed in individuals over 45 years old and is strongly linked to prolonged exposure to lung irritants such as cigarette smoke, air pollution, and occupational hazards (Mukherjee et al., 2009; Longe et al., 2006). Among these, cigarette smoking remains the most significant risk factor, with nearly half of all smokers developing some form of chronic bronchitis over their lifetime.

Clinical Presentation

The primary symptom of acute bronchitis is a persistent cough, often accompanied by sputum production, headache, fever, nasal congestion, and dyspnea. It is essential to differentiate acute bronchitis from other conditions such as asthma, pneumonia, and chronic obstructive pulmonary disease (COPD), as their management strategies differ (Wenzel et al., 2006). Chronic bronchitis, on the other hand, is defined by a productive cough lasting at least three months per year for two consecutive years. It leads to excessive mucus production, chronic airway inflammation, and progressive airway obstruction (Mukherjee et al., 2009; Brunton et al., 2004). Patients often experience worsening symptoms over time, including breathlessness, frequent respiratory infections, and increased susceptibility to exacerbations, which significantly impact their quality of life.

Common Symptoms of Bronchitis and Related Respiratory Conditions

Bronchitis, whether acute or chronic, presents with a variety of respiratory symptoms due to inflammation and mucus accumulation in the airways. The most commonly observed symptoms include sputum production, wheezing, chest pain, fever, and dyspnea. Sputum production is a hallmark of bronchitis, where excess mucus is secreted due to airway irritation. Wheezing, a whistling sound heard during breathing, is caused by narrowing of the bronchi due to inflammation and mucus buildup. Chest pain, often associated with persistent coughing, can cause discomfort and muscle strain. Fever is more commonly observed in acute bronchitis, indicating a viral or bacterial infection. Dyspnea, or

shortness of breath, results from airway obstruction due to excessive mucus production and inflammation, making breathing difficult (Knutson et al., 2002; Mufson et al., 2000).

A chronic cough, lasting more than eight weeks, is a common symptom of various lung diseases, including asthma, pulmonary fibrosis, lung cancer, and chronic obstructive pulmonary disease (COPD). Research from the Lung, Heart, Social Body (LEAD) cohort in Austria found that 9% of individuals aged 18 to 80 years suffer from a chronic cough, with prevalence increasing with age. Interestingly, a significant proportion of those affected were women who had never smoked (68.4%), highlighting the need for further studies to explore the underlying causes of chronic cough in non-smokers (Yang et al., 2023; Abozid et al., 2023).

COPD is a progressive and irreversible lung disease that results in chronic airway inflammation and obstruction, leading to long-term structural changes in the lungs. It is characterized by persistent cough, shortness of breath, wheezing, and frequent respiratory infections. Over the years, COPD has emerged as a leading cause of mortality worldwide. In 1990, COPD was the sixth leading cause of death globally, but in recent years, it has become the third most common cause of death (Sharifi et al., 2015). According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is a preventable and treatable disease, yet disparities in diagnosis exist across different regions, including North America, Europe, Oceania, Africa, the Middle East, and South Asia. Over-diagnosis and under-diagnosis remain major concerns, leading to improper treatment and poor disease management (Ho et al., 2019).

Bronchiectasis, another chronic lung condition, is characterized by abnormal, irreversible dilation of the bronchi, resulting in mucus accumulation, frequent infections, and airflow obstruction. This condition can develop due to recurrent respiratory infections, inflammatory diseases, autoimmune disorders, and genetic factors such as cystic fibrosis. Globally, tuberculosis (TB) and pneumonia are among the leading causes of bronchiectasis, particularly in low- and middle-income countries. In India, the Indian Bronchiectasis Registry (EMBARC-India), established in 2015 in collaboration with the European Multicentre Bronchiectasis Audit and

Research Collaboration, aims to provide valuable data on the epidemiology and progression of bronchiectasis in the country (Dhar et al., 2023).

The increasing global burden of bronchitis, COPD, and bronchiectasis emphasizes the need for early diagnosis, effective treatment strategies, and preventive measures to improve patient outcomes. Advancements in diagnostic tools, targeted therapies, and public health initiatives will play a crucial role in managing these respiratory conditions and reducing associated morbidity and mortality.



Fig:1 Here is a detailed medical illustration comparing healthy lungs, bronchitis, and COPD. It visually highlights the differences in airway structure, mucus production, and airflow obstruction.

Chronic Cough and Its Implications:

Chronic cough can be a symptom of several lung conditions, including asthma, pulmonary fibrosis, lung cancer, and chronic obstructive pulmonary disease (COPD). Data from the Lung, Heart, Social Body (LEAD) cohort in Austria found that 9% of people aged 18 to 80 had a chronic cough, with prevalence increasing with age. Notably, chronic cough was more common in women who had never smoked, at 68.4% (Yang et al., 2023; Abozid et al., 2023).

Chronic Obstructive Pulmonary Disease (COPD):

COPD is distinguished by chronic inflammation and irreversible airway obstruction, which results in anatomical

abnormalities in the lungs. COPD was the sixth greatest cause of death in the globe in 1990, but it has subsequently risen to third place (Sharifi et al., 2015). COPD, according to the Global Initiative for Chronic Obstructive Lung condition (GOLD), is a common, preventable, and treatable lung condition characterized by persistent breathing problems. However, COPD diagnosis varies across geographical locations, including North America, Europe, Oceania, Africa, the Middle East, and South Asia, with over- and under-diagnosis influencing patient outcomes (Ho et al., 2019).

Bronchiectasis and Its Impact:

Bronchiectasis can result from infections, inflammatory conditions, autoimmune disorders, and genetic factors. Globally, tuberculosis (TB) and pneumonia are leading causes. The Indian Bronchiectasis Registry (EMBARC-India), founded in 2015 in partnership with the European Multicentre Bronchiectasis Audit and Research partnership, intends to give information on the evolution of bronchiectasis in India (Dhar et al., 2023).

Risk Factors for COPD:

Being underweight (BMI below 18.5 kg/m²) significantly elevates the risk of developing COPD. Several studies have observed a high incidence of COPD in underweight individuals, while others suggest a correlation between higher BMI and increased COPD prevalence. Spirometry remains a key diagnostic tool for COPD (Adeloye et al., 2022). COPD can worsen when respiratory symptoms flare up, contributing to disease progression. Acute Exacerbations of COPD (AECOPD) are caused by respiratory infections, exposure to irritants, and other health issues, resulting in a continuing reduction in lung function and decreasing survival chances (Hogea et al., 2020). TB has also been found to increase the activity of enzymes that break down lung structural components, impairing lung function (Fan et al., 2021).

Diagnosis of Bronchitis on the basis of previous analysis and results

The diagnosis of bronchitis is a multifaceted process that relies on clinical evaluation, patient history, and various diagnostic tests to distinguish it from other respiratory conditions. Physicians begin by assessing the patient's symptoms, which typically

include a persistent cough, mucus production, wheezing, and shortness of breath. A thorough physical examination is conducted, often involving auscultation of the lungs to detect abnormal breath sounds such as wheezing or crackles, which may indicate airway inflammation or obstruction.

Imaging techniques, such as chest X-rays, are frequently used to confirm the diagnosis and rule out other illnesses, such as pneumonia or chronic obstructive pulmonary disease. While a chest X-ray may not always be necessary for cases of acute bronchitis, it is particularly useful when pneumonia is suspected, especially in patients presenting with fever, tachypnea, or severe respiratory distress. Additionally, pulmonary function tests (PFTs), including spirometry, play a crucial role in evaluating airflow limitation, particularly in patients with recurrent episodes or suspected chronic bronchitis. These tests help differentiate bronchitis from asthma and COPD, where airflow obstruction may be persistent. Laboratory investigations, such as blood tests, may also be performed to assess markers of systemic inflammation or infection. Elevated white blood cell (WBC) counts and C-reactive protein (CRP) levels can indicate an underlying bacterial or viral infection, though they are not specific to bronchitis. In cases where bacterial bronchitis is suspected, sputum cultures may be used to identify the causative pathogen and guide antibiotic therapy. Furthermore, the duration of symptoms serves as a significant diagnostic feature; acute bronchitis normally lasts for a few weeks, whereas chronic bronchitis is defined by an active cough persisting for at least three months in two consecutive years (NHLBI, NIH, 2022). Overall, the diagnosis of bronchitis requires a comprehensive assessment integrating clinical findings with diagnostic tools to ensure accurate differentiation from other respiratory illnesses. While acute bronchitis is often self-limiting and viral in origin, chronic bronchitis necessitates further investigation due to its association with COPD and long-term lung damage. Future advancements in molecular diagnostics and imaging technologies may further enhance the accuracy and efficiency of bronchitis diagnosis, enabling more personalized and effective treatment strategies.

Traditional and Alternative Treatments for Respiratory Conditions:

Acupoint herbal patching (AHP) is a treatment method that stimulates acupuncture points using herbal remedies to enhance immunity (Jun et al., 2019). Antibiotics, particularly macrolides like azithromycin, are commonly used to treat bacterial respiratory infections, including cystic fibrosis, bronchiectasis, asthma, and COPD (Dhar et al., 2021). A study in the Eastern Ghats of Andhra Pradesh, India, identified 84 medicinal plants used for respiratory conditions, including mint, sage, lemon, ginger, and thyme (Shawarb et al., 2023).

Treatments:

The management of bronchitis primarily depends on whether the condition is acute or chronic. Acute bronchitis is typically self-limiting and often results from viral infections, requiring mainly supportive care rather than specific pharmacological treatment. In most cases, antibiotics are unnecessary unless a bacterial infection is strongly suspected, which is uncommon. Instead, symptom relief and airway management remain the primary focus of treatment.

For patients experiencing significant bronchospasm or wheezing, bronchodilators such as albuterol may be prescribed to relax the airway muscles and improve airflow. In more severe cases, particularly in patients with underlying respiratory conditions, oxygen therapy may be necessary to alleviate hypoxia and improve breathing efficiency. Cough management is another critical aspect of treatment, and the approach depends on the nature of the cough. Protussive therapy is recommended when mucus clearance from the airways is necessary, helping to facilitate expectoration and prevent mucus buildup. Conversely, antitussive therapy is used to suppress persistent, dry, and non-productive coughs that interfere with sleep or daily activities. A commonly used antitussive, dextromethorphan, works by inhibiting the cough reflex in the brainstem, making it particularly useful for managing a persistent, nagging cough (Knutson et al., 2002; Irwin et al., 1993). In addition to pharmacological therapies, non-pharmacologic measures such as hydration, humidified air, and relaxation are critical to recovery. Staying hydrated thins mucus production, making it simpler to clear the airways, whilst humidification soothes airway irritation and reduces cough

severity. Patients with risk factors for chronic bronchitis, such as smokers or individuals with occupational lung exposure, are advised to minimize exposure to irritants and consider lifestyle modifications to prevent recurrent episodes.

Treatment methods for chronic bronchitis, a critical component of chronic obstructive pulmonary disease (COPD), may include long-term bronchodilator therapy, corticosteroids to reduce airway inflammation, pulmonary rehabilitation, and, in advanced instances, supplemental oxygen therapy. As research progresses, novel therapeutic approaches, including targeted anti-inflammatory therapies and regenerative medicine strategies, may provide improved outcomes for patients suffering from chronic bronchitis and its associated complications.

Environmental and Lifestyle Factors in COPD

Long-term exposure to traffic pollution, including particulate matter, sulfur dioxide, and nitrogen oxides, significantly contributes to COPD development (Stephen et al., 2018). Additionally, research from Austria, South Africa, Iceland, Poland, and Australia indicates that COPD prevalence is higher in non-smoking women than in non-smoking men (Denguezli et al., 2016). Long-term exposure to environmental toxins such as traffic pollution and biomass smoke contributes to bronchitis and COPD. The INSEARCH study in India found that chronic bronchitis prevalence in adults older than 35 years was 3.49% (Pati et al., 2018). Greenhouse farmers in China are at higher risk of respiratory issues due to enclosed workspaces and chemical exposure (Liu et al., 2015).

Impact of COVID-19 on respiratory diseases

The COVID-19 pandemic affected the prevalence and severity of respiratory diseases. A study found that hospitalizations for bronchiolitis in children under one year decreased by over 70% during the pandemic (Tian et al., 2023). Camporesi et al., 2022 found that during the 2021-2022 bronchiolitis season in Italy, SARS-CoV-2 was rarely the cause of bronchiolitis in children under 24 months old. Furthermore, RSV outbreaks were delayed by 12 weeks in French metropolitan regions due to non-pharmaceutical interventions (Curatola et al., 2023).The COVID-19 pandemic led to an increase in respiratory complications,

with long-term issues such as post-COVID syndrome (long COVID). Symptoms include chronic cough, fatigue, anosmia, and dyspnea, lasting months or even years post-infection (Lee et al., 2021).

National and Global COPD Management Policies

Several national and international policies aim to reduce COPD and chronic bronchitis prevalence. Nepal's healthcare policies focus on reducing deaths related to chronic respiratory diseases by 25% by 2025 (Adhikari et al., 2020). The World Health Organization's Global Action Plan for Pneumonia (GAPPD) aims to reduce pneumonia-related deaths by 75% of 2010 levels by 2025 (Troeger et al., 2018). The National Health Policy of India targets a 25% reduction in premature deaths from non-communicable diseases, including chronic respiratory diseases, by 2025 (Patil et al., 2022).

Conclusion and Future Directions

Bronchitis and COPD are common and serious conditions, new ways to diagnose, manage, and prevent them should be explored. Better diagnostic tools can help doctors detect and distinguish bronchitis early. New technologies like biomarker-based tests, artificial intelligence (AI) imaging, and molecular diagnostics can make diagnosis faster and more accurate. Wearable devices that track breathing in real-time can help monitor patients and catch problems early. Personalized medicine is another exciting possibility. Treatments tailored to a person's genes, environment, and lifestyle can improve outcomes and reduce side effects. Scientists are also looking into microbiome based treatments, such as probiotics and prebiotics, which may improve lung health and boost the immune system. More research into these approaches can lead to better treatment strategies. New treatments for bronchitis and COPD are also needed. Research into anti-inflammatory medicines and drugs that control mucus production can help manage symptoms and slow the disease. Regenerative medicine, including stem cell therapy, may help repair damaged lungs. Advanced drug delivery systems, like inhaled biologics and nanotechnology-based treatments, could make treatments more effective with fewer side effects. Preventing bronchitis and COPD is just as important as treating them. Stronger laws to reduce smoking, lower air pollution, and improve workplace safety can

help prevent these diseases. Educating people about the symptoms and risks of chronic bronchitis and COPD can encourage early medical attention, leading to better outcomes. The environment plays a big role in respiratory health. Air pollution, allergens, and extreme weather conditions can make bronchitis and COPD worse. More research is needed to understand how these factors contribute to the disease and to develop strategies to reduce their impact. The COVID-19 pandemic also affected respiratory diseases. More research is needed to understand how COVID-19 has influenced bronchitis and COPD in the long term. Studying post-COVID syndrome and how it affects lung health can help doctors find better ways to treat and prevent complications.

REFERENCES

Yang, X., Chung, K. F., & Huang, K. (2023). Worldwide prevalence, risk factors and burden of chronic cough in the general population: a narrative review. *Journal of thoracic disease*, *15*(4), 2300.

Abozid, H., Baxter, C. A., Hartl, S., Braun, E., Salomonsson, S., Breyer-Kohansal, R., ... &Burghuber, O. C. (2022). Distribution of chronic cough phenotypes in the general population: a cross-sectional analysis of the LEAD cohort in Austria. *Respiratory Medicine*, *192*, 106726.

Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., &Rudan, I. (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *The Lancet Respiratory Medicine*, *10*(5), 447-458.

Adhikari, T. B., Acharya, P., Högman, M., Neupane, D., Karki, A., Drews, A., ... &Kallestrup, P. (2020). Prevalence of chronic obstructive pulmonary disease and its associated factors in Nepal: Findings from a community-based household survey. *International journal of chronic obstructive pulmonary disease*, 2319-2331.

Breslow, L. (2002). Encyclopedia of public health. *(No Title)*.

Buhagiar, B. (2009). Acute bronchitis

Camporesi, A., Morello, R., Ferro, V., Pierantoni, L., Rocca, A., Lanari, M., ... &Buonsenso, D. (2022). Epidemiology, microbiology and severity of bronchiolitis in the first post-lockdown cold season in three different geographical areas in Italy: a prospective, observational study. *Children*, *9*(4), 491.

Curatola A, Graglia B, Ferretti S, Covino M, Pansini V, Eftimiadi G, Chiaretti A, Gatto A. The acute bronchiolitis rebound in children after COVID-19 restrictions: a retrospective, observational analysis. Acta Biomed. 2023 Feb 13;94(1):e2023031. doi: 10.23750/abm.v94i1.13552. PMID: 36786263; PMCID: PMC987502.

Denguezli, M., Daldoul, H., Harrabi, I., Gnatiuc, L., Coton, S., Burney, P., &Tabka, Z. (2016). COPD in nonsmokers: reports from the Tunisian population-based burden of obstructive lung disease study. *PloS one*, *11*(3), e0151981.

Dhar, R., Singh, S., Talwar, D., Mohan, B. M., Tripathi, S. K., Swarnakar, R., ... & EMBARC-India study group. (2023). Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. *European Respiratory Journal*, *61*(1).

Fan, H., Wu, F., Liu, J., Zeng, W., Zheng, S., Tian, H., ... & Ran, P. (2021). Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Annals of translational medicine*, *9*(5), 390

Feeney, A. S., Fendrick, A. M., &Quintiliani, R. (2004). Acute exacerbation of chronic bronchitis: a primary care consensus guideline. *Am. J. Manag. Care*, *10*(10), 689-696.

Ho, T., Cusack, R. P., Chaudhary, N., Satia, I., &Kurmi, O. P. (2019). Under-and over-diagnosis of COPD: a global perspective. *Breathe*, *15*(1), 24-35.

Hogea, S. P., Tudorache, E., Fildan, A. P., Fira-Mladinescu, O., Marc, M., &Oancea, C. (2020). Risk factors of chronic obstructive pulmonary disease exacerbations. *The clinical respiratory journal*, *14*(3), 183-197.

https://www.nhlbi.nih.gov/health/bronchitis.

Irwin, R. S., Curley, F. J., & Bennett, F. M. (1993). Appropriate use of antitussives and protussives: a practical review. *Drugs*, *46*, 80-91.

Jun, J. H., Kim, K. H., Song, E., Anga, L., & Park, S. (2019). Acupoint herbal patching for bronchitis: a protocol systematic review of randomized controlled trials. *Medicine*, *98*(29), e16368.

Kim, V., &Criner, G. J. (2013). Chronic bronchitis and chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*, *187*(3), 228-237.

Kinkade, S., & Long, N. A. (2016). Acute bronchitis. *American family physician*, *94*(7), 560-565.

Knutson, D., & Braun, C. (2002). Diagnosis and management of acute bronchitis. *American family physician*, *65*(10), 2039-2045.

Lee, J. H., Kang, S. Y., Yoo, Y., An, J., Park, S. Y., Lee, J. H., ... & Song, W. J. (2021). Epidemiology of adult chronic cough: disease burden, regional issues, and recent findings. *Asia Pacific Allergy*, *11*(4), e38

Liu, S., Ren, Y., Wen, D., Chen, Y., Chen, D., Li, L., ... & Wang, X. (2015). Prevalence and risk factors for COPD in greenhouse farmers: a large, cross-sectional survey of 5,880 farmers from northeast China. *International journal of chronic obstructive pulmonary disease*, 2097-2108.

Longe, J. L. (2015). The Gale encyclopedia of medicine.

Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. *Thorax.* 2001;56(2):109-114.

Mufson, M. A. (2000). Viral pharyngitis, laryngitis, croup and bronchitis. *Cecil Textbook of medicine. 21st ed. Philadelphia: Saunders*, 1793-4.

Mukherjee,T. K. & Indian Institute of Science Education and Research. (2009). Bronchitis: causes and treatment. In Handbook of Pulmonary Diseases: Etiology (Chapter 3). Nova Science Publishers, Inc.

Pati, S., Swain, S., Patel, S. K., Chauhan, A. S., Panda, N., Mahapatra, P., &Pati, S. (2018). An assessment of health-related quality of life among patients with chronic obstructive pulmonary diseases attending a tertiary care hospital in Bhubaneswar City, India. *Journal of family medicine and primary care*, *7*(5), 1047-1053.

Patil, S., Patil, R., Bhise, M., & Jadhav, A. (2022). Respiratory questionnaire-based analysis of awareness of COPD in a large multicenter rural population-based study in India. *Chronic Diseases and Translational Medicine*, *8*(04), 322-330.

Sharifi, H., Masjedi, M. R., Emami, H., Ghanei, M., Eslaminejad, A., Radmand, G., &Buist, S. (2015). Burden of obstructive lung disease study in Tehran: Prevalence and risk factors of chronic obstructive pulmonary disease. *Lung India*, *32*(6), 572-577.

Shawarb, N., Badrasawi, M., Qaoud, H. A., & Hussein, F. (2023). An ethno-botanical study of medicinal plants used for the management of respiratory tract disorders in northern parts of Palestine. *BMC Complementary Medicine and Therapies*, *23*(1), 387

Smith, M. P., Lown, M., Singh, S., Ireland, B., Hill, A. T., Linder, J. A., ... & Weinberger, M. (2020). Acute cough due to acute bronchitis in immunocompetent adult outpatients: CHEST Expert Panel Report. *Chest*, *157*(5), 1256-1265.

Stephen, P., Mahalakshmy, T., Manju, R., Laksham, K. B., Subramani, S., Panda, K., & Sarkar, S. (2018). High prevalence of chronic respiratory symptoms among autorickshaw drivers of urban Puducherry, South India. *Indian journal of occupational and environmental medicine*, *22*(1), 40-44.

Tian, J., Wang, X. Y., Zhang, L. L., Liu, M. J., Ai, J. H., Feng, G. S., ... &Xie, Z. D. (2023). Clinical epidemiology and disease burden of bronchiolitis in hospitalized children in China: a national cross-sectional study. *World Journal of Pediatrics*, *19*(9), 851-863.

Troeger, C., Blacker, B., Khalil, I. A., Rao, P. C., Cao, J., Zimsen, S. R., ... & Reiner, R. C. (2018). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet infectious diseases*, *18*(11), 1191-1210.

Wenzel, R. P., & Fowler III, A. A. (2006). Acute bronchitis. *New England journal of medicine*, *355*(20), 2125-2130.

Widysanto, A., Goldin, J., & Mathew, G. (2025). Chronic bronchitis. In *StatPearls [Internet]*. StatPearls Publishing